Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad s Life Science Q4 Sales Grew 16.4 Percent, Ex-Currency Benefits; Total Sales Jump 19.3 Percent

NEW YORK, Feb. 17 (GenomeWeb News) - Bio-Rad today reported a 19.3-percent increase in total net sales during then fourth quarter, while sales from its Life Science segment jumped 16.4 percent, excluding currency benefits.

Total net sales for the Hercules, Calif.-based life-sciences company increased to $307.9 million during the fourth quarter of 2004 from $258 million in the year-ago quarter. With currency benefits, net sales in the Life Science segment grew 21.6 percent to $148.5 million, the firm said.

 

Bio-Rad said that the revenue increase in Life Science was helped along by its August 2004 acquisition of MJ GeneWorks.

 

R&D spending during the three months ended Dec. 31, 2004, inched up to $31.9 million from $25.6 million year over year, Bio-Rad said.

 

The company said net income in the quarter fell to $17.1 million, or $.65 per share, from $19.2 million, or $.73 per share.

 

Bio-Rad said it had around $195.7 million in cash and equivalents and $165.9 million in short-term investments as of Dec. 31, 2004.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.